Gel given orphan drug status in Europe for CTCL

Submitted by Ross Bonander Fri 01/20/2012

Share on Tumblr

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

The privately held specialty pharmaceutical company Ceptaris Therapeutics has announced that the European Medicines Agency (EMA) has given Orphan Drug Designation to the company's investigational drug chlormethine gel (known as mechlorethamine gel in the United States) for the treatment of Cutaneous T-Cell Lymphoma (CTCL).

The gel was previously granted orphan drug status in the US by the US Food and Drug Administration.

The FDA is currently reviewing the New Drug Application (NDA) submitted by Ceptaris Therapeutics in July 2011 for mechlorethamine gel for the treatment of early stage favorable mycosis fungoides, a subtype of Cutaneous T-Cell Lymphoma (CTCL).

Source: MarketWatch

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Support Groups

SupportGroups.com

For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Find a Treatment Facility Near You

Click on a state below to find Lymphoma treatment options that could be right for you.

Select a State Below

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.